Technical Analysis for BNTC - Benitec Biopharma Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| NR7 | Range Contraction | 3.92% | |
| Gapped Up | Strength | 3.04% | |
| Gapped Down | Weakness | 8.26% | |
| 20 DMA Resistance | Bearish | 1.17% | |
| Gapped Up | Strength | 1.17% | |
| Slingshot Bearish | Bearish Swing Setup | 0.75% | |
| Gapped Up | Strength | 0.75% | |
| Pocket Pivot | Bullish Swing Setup | 5.58% |
| Alert | Time |
|---|---|
| Up 5% | about 7 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
| 20 DMA Resistance | about 9 hours ago |
| Rose Above 20 DMA | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
Benitec Biopharma Limited Description
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Macular Degeneration Small Cell Lung Cancer Genetic Engineering Hepatitis B Gene Expression Dystrophy Muscular Dystrophy Hepatitis C Huntington's Disease Wet Age Related Macular Degeneration HIV/Aids RNA Retinitis Rna Interference Ai Technology Clinical Applications Retinitis Pigmentosa Gene Silencing Chronic And Life Threatening Conditions Oculopharyngeal Muscular Dystrophy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.7 |
| 52 Week Low | 1.86 |
| Average Volume | 48,482 |
| 200-Day Moving Average | 4.75 |
| 50-Day Moving Average | 7.88 |
| 20-Day Moving Average | 7.21 |
| 10-Day Moving Average | 7.03 |
| Average True Range | 0.63 |
| RSI (14) | 48.19 |
| ADX | 21.48 |
| +DI | 19.34 |
| -DI | 24.96 |
| Chandelier Exit (Long, 3 ATRs) | 6.36 |
| Chandelier Exit (Short, 3 ATRs) | 7.64 |
| Upper Bollinger Bands | 7.81 |
| Lower Bollinger Band | 6.62 |
| Percent B (%b) | 0.54 |
| BandWidth | 16.50 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.24 |
| MACD Histogram | 0.0014 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.17 | ||||
| Resistance 3 (R3) | 8.15 | 7.83 | 8.02 | ||
| Resistance 2 (R2) | 7.83 | 7.60 | 7.84 | 7.97 | |
| Resistance 1 (R1) | 7.55 | 7.46 | 7.69 | 7.57 | 7.92 |
| Pivot Point | 7.23 | 7.23 | 7.30 | 7.24 | 7.23 |
| Support 1 (S1) | 6.94 | 7.00 | 7.08 | 6.96 | 6.61 |
| Support 2 (S2) | 6.62 | 6.85 | 6.63 | 6.56 | |
| Support 3 (S3) | 6.34 | 6.62 | 6.51 | ||
| Support 4 (S4) | 6.36 |
